Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
oxaliplatin
i
Other names:
1 OHP, 1670 RB, L OHP, NSC 266046, PR 54780, RP 54780, SR 96669, 1670 RB7, GSOX
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(57)
News
Trials
Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor, DNA cross linking agent
Related drugs:
‹
cisplatin (330)
gemcitabine (181)
temozolomide (114)
cytarabine (99)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
nedaplatin (6)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine-releasing intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
idarubicin hydrochloride (16)
ABBV-176 (1)
BP-C1 (0)
BTP-114 (0)
cisplatin liposomal (0)
mitomycin (0)
demplatin pegraglumer (0)
AP 5346 (0)
apaziquone (0)
SG 2000 (0)
AS-1-145 (0)
cisplatin (330)
gemcitabine (181)
temozolomide (114)
cytarabine (99)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
nedaplatin (6)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine-releasing intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
idarubicin hydrochloride (16)
ABBV-176 (1)
BP-C1 (0)
BTP-114 (0)
cisplatin liposomal (0)
mitomycin (0)
demplatin pegraglumer (0)
AP 5346 (0)
apaziquone (0)
SG 2000 (0)
AS-1-145 (0)
›
Associations
(57)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Colon Cancer
No biomarker
Colon Cancer
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Nasopharyngeal Carcinoma
No biomarker
Nasopharyngeal Carcinoma
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Germ Cell Tumors
No biomarker
Germ Cell Tumors
gemcitabine + paclitaxel + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + paclitaxel + oxaliplatin
Sensitive
:
A2
gemcitabine + paclitaxel + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + paclitaxel + oxaliplatin
Sensitive
:
A2
No biomarker
Gallbladder Cancer
No biomarker
Gallbladder Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
gemcitabine + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + oxaliplatin
Sensitive
:
A2
gemcitabine + oxaliplatin
Sensitive: A2 - Guideline
gemcitabine + oxaliplatin
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
oxaliplatin
Sensitive: A2 - Guideline
oxaliplatin
Sensitive
:
A2
HER-2 negative
Esophageal Cancer
HER-2 negative
Esophageal Cancer
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive
:
A2
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
capecitabine + oxaliplatin
Sensitive
:
A2
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
5-fluorouracil + oxaliplatin
Sensitive
:
B
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
5-fluorouracil + oxaliplatin
Sensitive
:
B
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
HMG-CoA reductase inhibitor + oxaliplatin
Sensitive: C2 – Inclusion Criteria
HMG-CoA reductase inhibitor + oxaliplatin
Sensitive
:
C2
HMG-CoA reductase inhibitor + oxaliplatin
Sensitive: C2 – Inclusion Criteria
HMG-CoA reductase inhibitor + oxaliplatin
Sensitive
:
C2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
PD-L1 inhibitor + oxaliplatin
Sensitive: C2 – Inclusion Criteria
PD-L1 inhibitor + oxaliplatin
Sensitive
:
C2
PD-L1 inhibitor + oxaliplatin
Sensitive: C2 – Inclusion Criteria
PD-L1 inhibitor + oxaliplatin
Sensitive
:
C2
ERCC1 overexpression
Colorectal Cancer
ERCC1 overexpression
Colorectal Cancer
oxaliplatin
Resistant: C3 – Early Trials
oxaliplatin
Resistant
:
C3
oxaliplatin
Resistant: C3 – Early Trials
oxaliplatin
Resistant
:
C3
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
5-fluorouracil + oxaliplatin
Resistant: C3 – Early Trials
5-fluorouracil + oxaliplatin
Resistant
:
C3
5-fluorouracil + oxaliplatin
Resistant: C3 – Early Trials
5-fluorouracil + oxaliplatin
Resistant
:
C3
MSH6 mutation
Colorectal Cancer
MSH6 mutation
Colorectal Cancer
5-fluorouracil + oxaliplatin
Resistant: C3 – Early Trials
5-fluorouracil + oxaliplatin
Resistant
:
C3
5-fluorouracil + oxaliplatin
Resistant: C3 – Early Trials
5-fluorouracil + oxaliplatin
Resistant
:
C3
MSH2 mutation
Colorectal Cancer
MSH2 mutation
Colorectal Cancer
5-fluorouracil + oxaliplatin
Resistant: C3 – Early Trials
5-fluorouracil + oxaliplatin
Resistant
:
C3
5-fluorouracil + oxaliplatin
Resistant: C3 – Early Trials
5-fluorouracil + oxaliplatin
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login